Replimune Group Inc diskutieren
Replimune Group Inc
WKN: A2JQN1 / Symbol: REPL / Name: Replimune Group / Aktie / Small Cap /
1,29 €
-76,49 %
Replimune Group, Inc. (NASDAQ: REPL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its price target raised by analysts at JPMorgan Chase & Co. from $16.00 to $19.00. They now have an "overweight" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its price target lowered by analysts at Jefferies Financial Group Inc. from $31.00 to $6.00. They now have a "buy" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to an "underperform" rating. They now have a $2.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating.
Ratings data for REPL provided by MarketBeat
Replimune Group (NASDAQ:REPL) had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co..
Ratings data for REPL provided by MarketBeat
Replimune Group (NASDAQ:REPL) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $18.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group (NASDAQ:REPL) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $13.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group (NASDAQ:REPL) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $13.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group (NASDAQ:REPL) had its price target raised by analysts at Wedbush from $18.00 to $19.00. They now have an "outperform" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group (NASDAQ:REPL) had its price target raised by analysts at Piper Sandler from $13.00 to $14.00. They now have an "overweight" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group (REPL) was downgraded by BMO Capital Markets from "market perform" to "underperform". They now have a $1.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group (REPL) had its "underweight" rating reaffirmed by JPMorgan Chase & Co..
Ratings data for REPL provided by MarketBeat
Replimune Group (REPL) had its "sell" rating reaffirmed by HC Wainwright.
Ratings data for REPL provided by MarketBeat
Neueste Beiträge
Barclays_PLC in Pacific Biosciences of California Inc. diskutieren